抄録
We investigated the effects of combination therapy with thromboxane A2 receptor antagonist (TxA2 RA: Ramatroban) and an antihistamine (Clemastine Fumarate) in patients with perennial allergic rhinitis. There was no significant difference in the three groups: combination group (n=20), the TxA2 RA (only Ramatroban) group (n=18) and the antihistamine (only Clemastine Fumarate) group (n=9) in terms of global improvement rating. Improvement was significantly better in the combination group compared to that in the TxA2 RA group two weeks after the start of administration (p<0.05). Moreover, intranasal rhinoscopic findings showed the mean nasal secretion score was significantly decreased in both the combination and TxA2 RA groups (p<0.05).
These findings suggest that TxA2 (Ramatroban) in combination with an antihistamine has beneficial effects on rhinorrhea in patients with perennial allergic rhinitis.
